Capital Analysts LLC Purchases 580 Shares of Johnson & Johnson (NYSE:JNJ)

Capital Analysts LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 1.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 43,027 shares of the company’s stock after buying an additional 580 shares during the period. Capital Analysts LLC’s holdings in Johnson & Johnson were worth $6,223,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. raised its position in shares of Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock valued at $562,723,000 after buying an additional 329,473 shares in the last quarter. Invst LLC increased its stake in shares of Johnson & Johnson by 394.0% in the 3rd quarter. Invst LLC now owns 10,290 shares of the company’s stock valued at $1,668,000 after purchasing an additional 8,207 shares during the last quarter. McIlrath & Eck LLC boosted its stake in Johnson & Johnson by 10.7% in the third quarter. McIlrath & Eck LLC now owns 2,892 shares of the company’s stock valued at $469,000 after buying an additional 279 shares in the last quarter. Passumpsic Savings Bank acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $262,000. Finally, Te Ahumairangi Investment Management Ltd lifted its stake in Johnson & Johnson by 10.1% in the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 50,765 shares of the company’s stock valued at $8,180,000 after purchasing an additional 4,640 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.3 %

NYSE:JNJ opened at $154.54 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a 50-day moving average of $159.48 and a 200-day moving average of $154.88. The company has a market cap of $372.42 billion, a PE ratio of 23.24, a PEG ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.36%. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is 57.84%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Morgan Stanley raised their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Wednesday, April 16th. Wells Fargo & Company decreased their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Leerink Partners cut their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Bank of America dropped their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, April 10th. Finally, Barclays lowered their price objective on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $171.82.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.